ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rolf Schoch who wrote ()	2/7/2000 12:22:00 AM
From: scott_jiminez	Read Replies (2) of 4474

Buy reiteration/Science paper comments. Robertson/Stevens reiterated a buy on 01/27/00 for Ariad. The title of their report is, 'New Focus on Drug Development and Gene Therapy. Reiterate Our Buy Rating'. This title can be viewed here bigcharts.multexinvestor.com by scrolling down to 'Reports Available for Purchase from Brokers'. I haven't read the actual report ($25!). Some thoughts about the Science paper: My compressed impression (reiterating PB)- which is similar to that of Aridor and Balch (A+B) who wrote the commentary - is that this approach opens up a completely new and potentially vast source of drug delivery. RAPID is not simply a twist of ARGENT; it addresses a completely different set of therapeutic regimens. There are certainly hurdles still to clear; OTOH, RAPID worked *in vivo* in a mouse model of diabetes (streptozotocin induced) in a completely dose-dependent and temporally extremely rapid manner. This is an amazing development. If you think I'm biased, I suggest you read the A+B commentary. Some quotes from it (my emphasis): -Remarkably, the research article by Rivera et al. on page 826 of this issue now demonstrates that the endoplasmic reticulum (ER), the first compartment in the secretory pathway, can also serve as a practical storage container for genetically engineered proteins such as insulin or growth hormone. -With this approach, storage and secretion of biologically active peptides and other proteins should be possible in any type of cell. -The ability to artificially regulate the secretory response in cells may enable us to adjust the delivery of hormones and enzymes introduced by gene therapy to correct a range of pathophysiological conditions. I think we have a real winner here folks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next